Compare IZEA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | ACRV |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.5M | 52.4M |
| IPO Year | 2010 | 2022 |
| Metric | IZEA | ACRV |
|---|---|---|
| Price | $3.61 | $1.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 67.1K | ★ 571.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,099,695.00 | N/A |
| Revenue This Year | $20.81 | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | $54.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.68 | $1.05 |
| 52 Week High | $5.86 | $3.56 |
| Indicator | IZEA | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 45.64 |
| Support Level | $3.44 | $1.23 |
| Resistance Level | $3.94 | $1.86 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 24.60 | 45.74 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.